Live
Home·Deals·Pharmaceuticals·Lilly acquires Ventyx Biosciences
SEO URLwww.firestrike.ai/deals/ventyx-biosciences-lilly-acquisition-2026-6
acquisitionAnnounced · Jan 9, 2026PharmaceuticalsSource · CredibleArticle · Factual
Ventyx Biosciences
Lilly
Ventyx Biosciences · Lilly

Lilly acquires Ventyx Biosciences

David Najork
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
ShareXLinkedInEmail
Deal value
$1B
Target
Ventyx Biosciences
Ventyx Biosciences
NASDAQ: VTYX · San Diego, California
Acquirer
Lilly
Lilly
Full Acquisition
Status
Pending

Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-09. Figures and status may change as filings and press coverage update.

Shares of Ventyx Biosciences surged over 60% following the announcement, while Eli Lilly saw its stock jump 3.3% in early trading, clearing a critical technical resistance level of $1,080

Deal timeline

Announced
Jan 9, 2026 · markets.financialcontent.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context

This transaction is classified in Pharmaceuticals with a reported deal value of $1B. Figures and status may change as sources update.

Sources: markets.financialcontent.com · Primary article · FireStrike proprietary index